Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone. (2nd November 2015)

• Record Type: Journal Article
• Authors: Ciniselli, Chiara Maura; De Bortoli, Maida; Taverna, Elena; Varinelli, Luca; Pizzamiglio, Sara; Veneroni, Silvia; Bonini, Chiara; Orlandi, Rosaria; Verderio, Paolo; Bongarzone, Italia
• Is Part Of: Expert review of proteomics. Volume 12:Number 6(2015)
• Page Start: 695
• Page End: 701
• Publication Date: 2015-11-02
• Subjects: benign breast disease -- BMP6 -- breast cancer -- early diagnosis -- erytroferrone -- erytropoiesis -- erytropoietin -- hepcidin -- IL-6 -- inflammation -- iron metabolism; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1586/14789450.2015.1099436
• Languages: English
• ISSNs: 1478-9450

Abstract

Abstract : Objective: Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the plasma levels of hepcidin, interleukin-6 (IL-6), erythropoietin (EPO) and erythroferrone (ERFE) in patients with benign breast disease or cancer. Methods: Plasma samples from a cohort of 131 patients (47 with benign breast disease and 84 with breast cancer) were subjected to the evaluation of hepcidin, IL-6, EPO and ERFE using SELDI-TOF-MS or immunoassays. Results: An elevated hepcidin was observed in malignant breast tumors compared to benign ones. No correlation was observed between hepcidin and IL-6, EPO or ERFE. Conclusion: Since the study included a cohort of patients (87%) with breast cancers smaller than 2 cm, these results may support our previous evidence about the potential role of hepcidin in breast cancer disease.